Genocea Biosciences Announces Collaboration To Characterize T Cell Responses To Cancer Antigens
3/3/2014 9:13:44 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches.
Help employers find you! Check out all the jobs and post your resume.
comments powered by